Drug intelligence / Profile preview

wetvax

Development stage: Phase 2
Lead developer: Sanofi
Modality: Vaccines & Immunotherapeutics
Administration: Percutaneous, Intradermal

Overview

Wetvax is a liquid formulation of live vaccinia virus used as a smallpox vaccine. It was manufactured by Aventis Pasteur and was part of the U.S. National Pharmaceutical Stockpile. Like other traditional smallpox vaccines, it works by exposing the body to a small dose of vaccinia virus, causing the immune system to develop immunity against smallpox.

Brand names: Wetvax
Other names: Aventis Pasteur Smallpox VaccineNIAID Smallpox Vaccineliquid smallpox vaccine

Beyond the preview

Go deeper on wetvax.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on wetvax.

Explore the full profile